About 7 in 10 people whose osteosarcoma has not spread are cured with chemotherapy and surgery, a rate that has barely changed since the 1980s. There is no reliable cure once it spreads or returns. Our view: the next gains will come from drugs that hunt down the cancer cells surgery leaves behind, not from stronger chemo.
This is Cure Checker's editorial assessment of published evidence, not medical advice. Treatment decisions belong with an oncologist, ideally at a sarcoma center that treats many bone tumors.
Please read first. This is an AI-generated hypothesis, written by Cure Checker's AI from published research. It is speculation, not an established finding. It is not a recommendation, not a prediction that a cure exists, and not medical advice. No doctors or scientists have reviewed it, and it may be wrong. Never start, stop, change or delay any treatment because of it. Talk with your oncologist.
Could a tumor-DNA blood test, taken after standard treatment ends, find people whose cancer is still hiding, months before a scan can? And could a cell-seeking drug given then prevent relapse better than waiting for tumors to appear? That needs a validated test and a trial that do not yet exist.
What would prove it wrong: if a positive blood test after treatment does not reliably come before relapse, or if treating then does not lower relapse.
Hypothesis written October 6, 2026. Cure Checker's AI will revisit it when major new evidence appears.
Newest first. Updated each morning as results, trial launches and papers are published.
A review of 31 studies with 2,006 people with osteosarcoma of the head and neck found chemotherapy was linked to longer overall survival (hazard ratio 0.75) and longer disease-free survival (0.79), mostly when given before surgery. Radiotherapy showed no survival benefit. It pools past studies rather than a randomized trial, and this form is rare (about 1% of head and neck cancers).
In mouse models, a drug that switches on the STING immune pathway first triggered fast tumor death driven by macrophages, then a T-cell attack and lasting immune memory. Some mice were cured. Researchers also found a STING activity signature that predicted survival in newly diagnosed patients. Early lab and animal work, not tested in people.
Final analysis: 72.7% of patients were alive at three years versus 45.8% in past patients from published studies (p = .0006). Only 41 people were treated, 4 were lost to follow-up, and there was no randomized comparison group. The numbers are company-reported. The company says it plans to file in the U.S., U.K., Europe and Australia in the fourth quarter of 2026; nothing is approved yet.
The company says the FDA agreed with its adaptive Phase 3 design after a statistical-methods meeting. It plans to start that trial in the U.K. in late 2026, and says it is still waiting on FDA decisions on rolling review. Company-reported; no approval yet.
Patients treated after lung tumors were removed: 71.2% alive at three years versus 45.8% in historical controls (p = .002). FDA statistical-methods meeting held mid-September.
Mapped tumors cell by cell. A cancer-cell state marked by ADAMTS12 is enriched in tumors that have spread, a possible marker and target.
NCI trial in relapsed osteosarcoma and neuroblastoma is suspended while safety data are reviewed.
A new drug candidate, not yet tested in people. First-in-human trial expected later in 2026.
Met its primary goal: longer progression-free survival than gemcitabine + docetaxel in relapsed osteosarcoma, with survival trending the same way. 117 patients, China.
ASB7 tags the protein ATF2 for destruction, switching on genes that help osteosarcoma colonize the lungs. A new drug target.
Tests a first-of-its-kind drug against MYC, a growth switch often amplified in osteosarcoma, in advanced high-grade disease.
Grows each patient's tumor in the lab and tests drugs on it to choose treatment.
Granted for relapsed or refractory osteosarcoma based on early ARTEMIS-002 data that included 42 osteosarcoma patients.
Did not significantly extend progression-free survival over chemo alone (6.5 vs 5.5 months) in 81 children and young adults.
Randomized trial in newly diagnosed patients under 40: does adding cabozantinib to standard chemo prevent relapse?
The cure rate for osteosarcoma that hasn't spread has stayed flat since the 1980s. The new wins are in relapsed and lung-spread disease, where options were weakest.
In the ARTEMIS-011 trial (117 patients, China), it kept the cancer in check longer than gemcitabine plus docetaxel, and survival trended the same way. It's an antibody that delivers chemo to cells marked with B7-H3. A filing in China is planned, and it has FDA breakthrough status.
A weakened, modified Listeria bacterium that trains the immune system to attack HER2. Three-year survival was 71.2% versus 45.8% in past patients (41 treated, p = .002). A rolling FDA application is under way, and the company is aiming for 2027 availability. Not yet tested against a randomized control group.
In the CABONE trial, 1 in 3 relapsed patients went 6+ months without the cancer growing. Now in AOST2032, which tests whether adding it to standard chemo from day one prevents relapse.
In SARC024 it doubled the time before the cancer grew (3.6 vs 1.7 months) compared with placebo. It's used off-label in the U.S. as a second-line option. It slows the cancer but doesn't cure it.
An immune stimulant added to chemo after surgery. Europe approved it, but the FDA did not, over concerns about how the trial was analyzed. It's the main approval gap between the U.S. and Europe.
Adding lenvatinib to ifosfamide and etoposide didn't significantly extend the time before the cancer grew (6.5 vs 5.5 months) in 81 young patients. A useful negative result: not every pill that blocks blood-vessel growth helps.
| Treatment | For | What it does |
|---|---|---|
| MAP chemotherapy (1980s) | Nearly all patients | High-dose methotrexate, doxorubicin and cisplatin, given before and after surgery. The backbone of cure. |
| Surgery | Every removable tumor | Removes the tumor with a margin of healthy tissue. Most patients today keep the limb. |
| Lung surgery | Spread to the lungs | Removing every lung nodule is the strongest predictor of survival once the cancer has spread. |
| Ifosfamide / etoposide, regorafenib, cabozantinib | Relapse | Second-line options that can slow the disease. None cures most patients. |
| Mifamurtide (Europe, 2009) | Non-metastatic | Immune stimulant added after surgery. Not FDA approved. |
No supplement prevents or cures osteosarcoma. Most "natural" claims come from lab dishes, not patients, and some supplements can interfere with chemo. We rate each by the strength of human evidence.
Kills osteosarcoma cells in lab dishes and mice. In people, only a small early pilot in advanced osteosarcoma has been run, with no proof of benefit. The body absorbs about 1% of what's swallowed.
Lab-only results. Concentrated extracts may interact with chemo, and green tea extract can strain the liver.
Doxorubicin and cisplatin work partly through oxidative damage. In a large breast-cancer study (SWOG S0221), taking antioxidants before and during chemo was linked to more relapses. Skip them unless your oncologist agrees.
Low levels are common in children and teens with cancer. It's reasonable to correct a measured deficiency for bone health. It isn't an anti-cancer treatment.
Structured rehab is how limb-sparing surgery turns into a working limb. Start early and keep it up.
MAP chemo causes nausea and mouth sores, and weight loss is common. Being undernourished is linked to more complications. Work with a dietitian.
Chemo and less activity can thin bones. Get enough calcium from food, plus weight-bearing activity when cleared.
After high-dose methotrexate, your team gives a carefully timed "rescue" of leucovorin (folinic acid). Extra folate from supplements can upset that balance, so ask before taking any.
Be careful: many multivitamins contain folic acid and antioxidants, which can affect how methotrexate rescue, doxorubicin and cisplatin work. Clinics selling "natural" or "immune" cancer cures can delay treatment that works. Tell the oncology team about everything you take.
Centers recognized for expertise in this condition, and communities of people living with it.
An NCI-designated Comprehensive Cancer Center that says its Sarcoma Center treats more osteosarcoma patients than any other U.S. cancer center (the center's own statement).
Designated an NCI Comprehensive Cancer Center and offers clinical trials for children, teens and young adults with osteosarcoma.
Says its doctors see about 175 patients with primary bone cancer each year and wrote the first detailed descriptions of osteosarcoma and Ewing sarcoma.
Described as Italy's leading national reference centre for sarcoma chemotherapy and surgery, treating an estimated 50% of Italian osteosarcoma and Ewing sarcoma patients.
These are centers recognized for expertise in this condition, not a ranking, and Cure Checker does not endorse or rate any facility. Outcomes depend on the individual. Ask your doctor which center fits your situation.
You don't have to face osteosarcoma alone. These groups connect patients, families and caregivers with people who understand. Most are free.
A pediatric osteosarcoma nonprofit. Its Ambassador Agents program connects newly diagnosed families with survivor families.
Get connected ↗Peer mentors and Cozy Cancer Corner, a young-adult group started by two osteosarcoma survivors.
Find support ↗A free service that connects families with osteosarcoma specialists to answer treatment questions.
Learn more ↗Information and a support line from the UK sarcoma charity.
Get support ↗A UK charity focused on primary bone cancers, including osteosarcoma.
Get support ↗An online community where patients and caregivers learn from each other.
Join ↗A large, general cancer support community on Reddit.
Open on Reddit ↗Several private osteosarcoma and bone-cancer family groups exist. This link searches Facebook (a login is required).
Search Facebook ↗Most osteosarcoma patients are children, teens and young adults, so many groups are built for parents and families. MIB Agents also runs a bereavement program for parents and siblings.
Before you join: support groups share experiences, not medical advice. Check anything about treatment with your doctor. Think about your privacy, because Reddit and many forums are public, and never share passwords or financial details. Cure Checker isn't affiliated with these groups.
Chemo and surgery are the same nearly everywhere. The differences are in the extras: one immune drug approved only in Europe, targeted pills that Chinese guidelines recommend, and a new drug whose Phase 3 ran entirely in China.
| Treatment | U.S. | EU | UK | Canada | Japan | S. Korea | China | Australia | Switz. |
|---|---|---|---|---|---|---|---|---|---|
| MAP chemotherapyStandard first-line | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Mifamurtide (Mepact)Non-metastatic, after surgery | Not approved 2007 | 2009 | 2009 | — | — | — | — | — | — |
| AnlotinibAdvanced bone sarcoma | — | — | — | — | — | — | Guideline, Class I | — | — |
| Regorafenib / cabozantinibRelapse, off-label | Guideline option | Trial | — | — | — | — | — | — | — |
| Ris-Rez (B7-H3 ADC)Relapsed disease | Breakthrough | — | — | — | — | — | Filing planned | — | — |
| OST-HER2After lung tumors removed | Filing 2026 | Filing planned | Filing planned | — | — | — | — | Filing planned | — |
Added to chemo after surgery for osteosarcoma that hasn't spread. The FDA turned it down, so U.S. families usually can only get it by importing it or through a trial abroad.
Chinese oncology guidelines (CSCO) rate anlotinib a Class I second-line option for advanced bone sarcoma. Apatinib is widely paired with chemo for relapse. Neither is approved in the U.S.
The winning Phase 3 enrolled only patients in China, and the first filing will be there. Outside China, GSK holds the rights and FDA breakthrough status. Ask about expanded access.
Osteosarcoma is a cancer of the cells that build bone. It strikes most often during the teenage growth spurt, in the fastest-growing bones. There's no single faulty protein to blame. Instead, the tumor's DNA is shattered, and the "guardian" gene TP53 is broken in most cases.
Live numbers and the newest entries from the world's main trial registries and medical databases. Most of this loads fresh each time you open the page.
Loading live data from ClinicalTrials.gov…
Loading…
Loading…
Loading…
| Medicine | Brand | FDA application | Original approval |
|---|
From Drugs@FDA via FDA's openFDA service. Some older brands are missing from FDA's open data, and newly approved drugs can take a few weeks to appear. An approval may be for a different disease than this one.
The WHO's ICTRP gathers trials from registries worldwide, including China, Japan, India, Iran, Australia and Brazil. Cochrane CENTRAL and OpenMD don't allow automated access, so they're linked here for you to search directly.
These sarcoma organizations help families affected by osteosarcoma and other sarcomas pay for specific costs of care. Funds are limited and rules vary, so contact each one directly.
Pays back travel and lodging costs of taking part in a sarcoma clinical trial, up to $5,000 per patient. Patients diagnosed at ages 15 to 39 are funded through Jordan's Dream Fund. Awards depend on available funds.
See the program ↗Pays back up to $1,000 of out-of-pocket costs, such as travel and the evaluation itself, for one second-opinion visit with a sarcoma specialist. You apply after the visit, by quarterly deadlines.
See the program ↗Books and pays for flights, a hotel and local transport so a sarcoma patient and one companion can reach a specialist center far from home. Each request is reviewed against current funding.
See how to apply ↗$250 grants for sarcoma patients in active treatment, once every 12 months. A hospital social worker, navigator or nurse applies on the patient's behalf. Funds are limited.
See the program ↗Before you apply: Cure Checker does not run, verify or endorse these organizations, and being listed is not a promise of help. Funds are limited and rules change, so confirm eligibility and details with each organization. Be careful of anyone who asks for payment up front or for your bank login to 'release' a grant.
Everything this report is based on, grouped by section. Checked October 2, 2026.
Vitamin D, nutrition, bone-health and rehab guidance reflects standard supportive-care practice rather than a single study. Expert care centers: Volume and "largest" statements for MD Anderson, MSK and Rizzoli come from the centers' or their network's own pages and were not independently confirmed. No second European center could be verified. Financial help: checked October 6, 2026. None of these funds is limited to osteosarcoma; each covers people with any sarcoma. Beat the Odds Sarcoma Fund is a new volunteer-run charity with a short track record. The Bone Cancer Research Trust (UK) is reported to give financial assistance grants, but its site blocked automated reading, so it is not listed. No copay charity listed an open fund that covers osteosarcoma (Patient Advocate Foundation's sarcoma fund is for soft tissue sarcoma only).